Larimar Therapeutics (LRMR) director Flynn bought 5,000,000 shares for $25M at $5.00
Insider transactions reported
James E Flynn (* Director by Deputization at Larimar Therapeutics Inc., LRMR) reported that they bought 5,000,000 shares for $25M at $5.00 on Feb 27, 2026. After these transactions the filing shows 10,622,928 shares held indirectly (Through Deerfield Private Design Fund III, L.P.) and 10,622,957 shares held indirectly (Through Deerfield Private Design Fund IV, L.P.).
- Reporting person
- Flynn James E
- Role
- * Director by Deputization
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Feb 27, 2026 | Open-market purchase (P) | Common Stock1, 2 | +1,084,010 | $5.00 | $5.42M | 10,622,928 indirect |
| Feb 27, 2026 | Open-market purchase (P) | Common Stock1, 2 | +1,084,012 | $5.00 | $5.42M | 10,622,957 indirect |
| Feb 27, 2026 | Open-market purchase (P) | Common Stock1, 2 | +831,978 | $5.00 | $4.16M | 8,153,107 indirect |
| Feb 27, 2026 | Open-market purchase (P) | Common Stock1, 2 | +2,000,000 | $5.00 | $10M | 6,207,982 indirect |
Holdings before and after
- Common Stock: 9,538,918 to 10,622,928 indirect, Through Deerfield Private Design Fund III, L.P.
- Common Stock: 9,538,945 to 10,622,957 indirect, Through Deerfield Private Design Fund IV, L.P.
- Common Stock: 7,321,129 to 8,153,107 indirect, Through Deerfield Healthcare Innovations Fund, L.P.
- Common Stock: 4,207,982 to 6,207,982 indirect, Through Deerfield Partners, L.P.
Footnotes from the filing
- 1. This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the Reporting Persons ). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. ( Fund III ). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. ( Fund IV ). Deerfield Mgmt HIF, L.P. is the general partner of Deerfield Healthcare Innovations Fund, L.P. ( Deerfield HIF ). Deerfield Mgmt, L.P. is the general partner of Deerfield Partners, L.P. ( Deerfield Partners ). Deerfield Management Company, L.P. is the investment manager of Deerfield Partners, L.P., Fund III, Fund IV and Deerfield HIF (collectively, the Funds ). James E. Flynn is the sole manager of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Mgmt HIF, L.P., Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
- 2. In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Transaction codes in this filing
- Open-market purchase:
- Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
FAQ
What did Flynn report in this LRMR Form 4?
James E Flynn (* Director by Deputization at Larimar Therapeutics Inc., LRMR) reported that they bought 5,000,000 shares for $25M at $5.00 on Feb 27, 2026. After these transactions the filing shows 10,622,928 shares held indirectly (Through Deerfield Private Design Fund III, L.P.) and 10,622,957 shares held indirectly (Through Deerfield Private Design Fund IV, L.P.).
How many LRMR shares does Flynn hold after this filing?
The filing shows 10,622,928 shares held indirectly (Through Deerfield Private Design Fund III, L.P.), 10,622,957 shares held indirectly (Through Deerfield Private Design Fund IV, L.P.), 8,153,107 shares held indirectly (Through Deerfield Healthcare Innovations Fund, L.P.) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code P mean on an SEC Form 4?
Code P marks a purchase in the open market or a private deal. The insider paid for these securities.
Historical context for LRMR
Across the 4 sessions after earlier LRMR headlines, the stock closed higher 1 times and lower 3 times, with a median move of 11.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | LRMR | SPY |
|---|---|---|---|
| Feb 26, 2026 | Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offeringand 1 other headline that session | -7.2% | -0.6% |
| Feb 24, 2026 | Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 | +31.3% | +0.7% |
| Dec 18, 2025 | Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | -0.9% | +0.8% |
| Nov 5, 2025 | Larimar Therapeutics Reports Third Quarter 2025 Financial Results | -15.3% | +0.3% |
Earlier insider filings at LRMR
- Mar 2, 2026Director Hamilton Thomas Edward bought $500,000 worth of shares (100,000 units at $5.00), increasing direct ownership by 18% to 664,798 units (SEC Form 4)
- Mar 2, 2026Director Thomas Frank E bought $25,000 worth of shares (5,000 units at $5.00), increasing direct ownership by 250% to 7,000 units (SEC Form 4)
- Mar 2, 2026Director Sherman Jeffrey W bought $25,000 worth of shares (5,000 units at $5.00) (SEC Form 4)
- Jan 27, 2026Chief Development Officer Shankar Gopi was granted 25,637 shares, increasing direct ownership by 50% to 76,443 units (SEC Form 4)
- Jan 27, 2026Chief Medical Officer Clayton Russell was granted 25,637 shares, increasing direct ownership by 56% to 71,443 units (SEC Form 4)
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Follow LRMR and get a push notification the moment its next story breaks.